The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy.
Ontology highlight
ABSTRACT: OBJECTIVES:Transforming growth factor-beta (TGF-?) is a multifunctional regulatory factor. Here we measured serum soluble TGF-? (sTGF-?) levels and evaluated its dynamics and prognostic capabilities during chemotherapy in unresectable pancreatic cancer patients. METHODS:We prospectively enrolled 60 patients treated with FOLFIRINOX as the first-line palliative chemotherapy. We collected blood samples at the time of diagnosis, first response assessment, and disease progression and measured serum sTGF-? using an enzyme-linked immunosorbent assay. RESULTS:The patients' median overall survival (OS) and progression-free survival (PFS) were 10.3 (95% confidence interval [CI], 8.5-12.1) and 6.5 (95% CI, 4.9-8.1) months, respectively. Patients with low sTGF-? at diagnosis (<31.2 ng/mL) had better OS and PFS than patients with high sTGF-?, respectively, (OS, 13.7 vs 9.2 months; hazard ratio [HR], 2.602; P = .004; PFS, 9.0 vs 5.8 months; HR, 2.010; P = .034). At the time of disease progression, sTGF-? was increased compared with that of diagnosis (mean, 26.4 vs 23.9 ng/mL). In particular, sTGF-? was significantly increased at disease progression in patients with a partial response (mean, 25.7 vs 31.0 ng/mL; P = .049). CONCLUSIONS:Pretreatment sTGF-? levels can serve as a prognostic indicator in unresectable pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Likewise, the dynamics of sTGF-? during chemotherapy have prognostic value.
SUBMITTER: Park H
PROVIDER: S-EPMC6943145 | biostudies-literature | 2020 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA